Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Authors
Lepage, CDahan, L
Bouarioua, N
Toumpanakis, C
Legoux, J
Le Malicot, K
Guimbaud, R
Smith, D
Tougeron, D
Lievre, A
Cadiot, G
Di Fiore, F
Bouhier-Leporrier, K
Hentic, O
Faroux, R
Pavel, M
Borbath, I
Valle, Juan W
Rinke, A
Scoazec, J
Ducreux, M
Walter, T
Affiliation
Department of Digestive Oncology, Burgundy Franche-Conte University, University hospital Dijon, Dijon, FranceIssue Date
2017-03-11
Metadata
Show full item recordAbstract
Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.Citation
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. 2017, 49(5):568-571 Dig Liver DisJournal
Digestive and Liver DiseaseDOI
10.1016/j.dld.2017.02.004PubMed ID
28292641Type
ArticleLanguage
enISSN
1878-3562ae974a485f413a2113503eed53cd6c53
10.1016/j.dld.2017.02.004
Scopus Count
Collections
Related articles
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
- Authors: Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators.
- Issue date: 2014 Jul 17
- Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
- Authors: Buil-Bruna N, Dehez M, Manon A, Nguyen TX, Trocóniz IF
- Issue date: 2016 May
- Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
- Authors: Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L
- Issue date: 2006 Nov 15
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
- Authors: Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, CLARINET Investigators.
- Issue date: 2016 Mar
- The safety of lanreotide for neuroendocrine tumor.
- Authors: Godara A, Siddiqui NS, Byrne MM, Saif MW
- Issue date: 2019 Jan